The initial product label for Profilate by Alpha/Abbott Laboratories included a warning which stated that "Patients with mild deficiencies who consequently have not received multiple transfusions of blood, or blood products, are at greatest risk. Under such circumstances, the benefits of Profilate administration must be weighed carefully against the risk of viral hepatitis"